X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins

被引:28
作者
Messori, L. [1 ]
Balerna, A. [2 ]
Ascone, I. [3 ]
Castellano, C. [4 ]
Gabbiani, C. [1 ]
Casini, A. [5 ]
Marchioni, C. [6 ]
Jaouen, G. [3 ]
Castellano, A. Congiu [6 ]
机构
[1] Univ Florence, Dept Chem, I-50019 Florence, Italy
[2] INFN LNF, I-00044 Frascati, Italy
[3] CNRS, UMR 7223, Chim ParisTech, Lab Charles Friedel, F-75231 Paris 05, France
[4] Univ Milan, Dipartimento Chim Strutturale & Stereochim Inorga, I-20133 Milan, Italy
[5] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
[6] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy
来源
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 2011年 / 16卷 / 03期
基金
瑞士国家科学基金会;
关键词
X-ray absorption spectroscopy; Gold compound; Protein; Cytotoxicity; HUMAN BLOOD-PLASMA; GOLD(III) COMPLEXES; SOLUTION CHEMISTRY; ANTICANCER AGENTS; CANCER-CELLS; BINDING; ALBUMIN; METALS; METALLODRUGS; AURANOFIN;
D O I
10.1007/s00775-010-0748-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gold metallodrugs form a class of promising antiproliferative agents showing a high propensity to react with proteins. We exploit here X-ray absorption spectroscopy (XAS) methods [both X-ray absorption near-edge spectroscopy (XANES) and extended X-ray absorption fine structure (EXAFS)] to gain insight into the nature of the adducts formed between three representative gold(I, III) metallodrugs (i.e., auranofin, [Au(2,2'-bipyridine)(OH)(2)](PF6), Aubipy, and dinuclear [Au-2(6,6'-dimethyl-2,2'-bipyridine)(2)(mu-O)(2)](PF6)(2), Auoxo6) and two major plasma proteins, namely, bovine serum albumin (BSA) and human serum apotransferrin (apoTf). The following metallodrug-protein systems were investigated in depth: auranofin/apoTf, Aubipy/BSA, and Auoxo6/apoTf. XANES spectra revealed that auranofin, upon protein binding, conserves its gold(I) oxidation state. Protein binding most probably takes place through release of the thiosugar ligand and its subsequent replacement by a thiol (or a thioether) from the protein. This hypothesis is independently supported by EXAFS results. In contrast, the reactions of Aubipy with serum albumin and of Auoxo6 with serum apoTf invariantly result in gold(III) to gold(I) reduction. Gold(III) reduction, clearly documented by XANES, is accompanied, in both cases, by release of the bipyridyl ligands; for Auoxo6 cleavage of the gold-gold dioxo bridge is also observed. Gold(III) reduction leads to formation of protein-bound gold(I) species, with deeply modified metal coordination environments, as evidenced by EXAFS. In these adducts, the gold(I) centers are probably anchored to the protein through nitrogen donors. In general, these two XAS methods, i.e., XANES and EXAFS, used here jointly, allowed us to gain independent structural information on metallodrug/protein systems; detailed insight into the gold oxidation state and the local environment of protein-bound metal atoms was achieved in the various cases.
引用
收藏
页码:491 / 499
页数:9
相关论文
共 45 条
[11]   Interactions of antitumoral platinum-group metallodrugs with albumin [J].
Espósito, BP ;
Najjar, R .
COORDINATION CHEMISTRY REVIEWS, 2002, 232 (1-2) :137-149
[12]   Imaging Metals in Proteins by Combining Electrophoresis with Rapid X-ray Fluorescence Mapping [J].
Finney, Lydia ;
Chishti, Yasmin ;
Khare, Tripti ;
Giometti, Carol ;
Levina, Aviva ;
Lay, Peter A. ;
Vogt, Stefan .
ACS CHEMICAL BIOLOGY, 2010, 5 (06) :577-587
[13]   Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: Relationships to biological properties [J].
Gabbiani, Chiara ;
Casini, Angela ;
Messori, Luigi ;
Guerri, Annalisa ;
Cinellu, Maria Agostina ;
Mlnghetti, Giovanni ;
Corsini, Maddalena ;
Rosani, Claudia ;
Zanello, Piero ;
Arca, Massimiliano .
INORGANIC CHEMISTRY, 2008, 47 (07) :2368-2379
[14]   Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs [J].
Gabbiani, Chiara ;
Magherini, Francesca ;
Modesti, Alessandra ;
Messori, Luigi .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (04) :324-337
[15]   XAS investigations into the mechanism(s) of Au(III) binding and reduction by alfalfa biomass [J].
Gardea-Torresdey, JL ;
Tiemann, KJ ;
Parsons, JG ;
Gamez, G ;
Herrera, I ;
Jose-Yacaman, M .
MICROCHEMICAL JOURNAL, 2002, 71 (2-3) :193-204
[16]   The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours [J].
Hall, Matthew D. ;
Alderden, Rebecca A. ;
Zhang, Mel ;
Beale, Philip J. ;
Cai, Zhonghou ;
Lai, Barry ;
Stampfl, Anton P. J. ;
Hambley, Trevor W. .
JOURNAL OF STRUCTURAL BIOLOGY, 2006, 155 (01) :38-44
[17]   XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents [J].
Hall, MD ;
Foran, GJ ;
Zhang, M ;
Beale, PJ ;
Hambley, TW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (25) :7524-7525
[18]   Seleno-Auranofin (Et3PAuSe-tagl): Synthesis, Spectroscopic (EXAFS, 197Au Mossbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) Characterization, Biological Activity, and Rapid Serum Albumin-Induced Triethylphosphine Oxide Generation [J].
Hill, David T. ;
Isab, Anvarhusein A. ;
Griswold, Don E. ;
DiMartino, Michael J. ;
Matz, Elizabeth D. ;
Figueroa, Angel L. ;
Wawro, Joyce E. ;
DeBrosse, Charles ;
Reiff, William M. ;
Elder, Richard C. ;
Jones, Benjamin ;
Webb, James W. ;
Shaw, C. Frank, III .
INORGANIC CHEMISTRY, 2010, 49 (17) :7663-7675
[19]  
HILL DT, 1980, CRYST STRUCT COMMUN, V9, P679
[20]   Cisplatin binding sites on human albumin [J].
Ivanov, AI ;
Christodoulou, J ;
Parkinson, JA ;
Barnham, KJ ;
Tucker, A ;
Woodrow, J ;
Sadler, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (24) :14721-14730